X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (63) 63
humans (50) 50
pharmacology & pharmacy (40) 40
animals (26) 26
male (21) 21
pharmacokinetics (20) 20
article (18) 18
cancer (16) 16
oncology (15) 15
biochemistry & molecular biology (13) 13
female (11) 11
mice (11) 11
middle aged (11) 11
adult (10) 10
cell line, tumor (10) 10
metabolism (10) 10
tumors (10) 10
aged (9) 9
immunoproteasome (9) 9
liver (9) 9
pharmacy (9) 9
proteasome endopeptidase complex - metabolism (9) 9
proteasome inhibitors (9) 9
analysis (8) 8
cells (8) 8
chemistry, medicinal (8) 8
expression (8) 8
neoplasms - drug therapy (8) 8
rats (8) 8
care and treatment (7) 7
chemistry (7) 7
dose-response relationship, drug (7) 7
liver - metabolism (7) 7
permeability (7) 7
pharmacology (7) 7
antineoplastic agents - therapeutic use (6) 6
cell line (6) 6
inhibitors (6) 6
kinetics (6) 6
metallurgy (6) 6
multiple myeloma (6) 6
nanoparticles (6) 6
pharmacology/toxicology (6) 6
proteins (6) 6
20s proteasome (5) 5
albumin (5) 5
antineoplastic agents - pharmacokinetics (5) 5
biochemistry (5) 5
carfilzomib (5) 5
chemotherapy (5) 5
clinical trials (5) 5
drug therapy (5) 5
drugstores (5) 5
electricity (5) 5
human liver (5) 5
medicine, research & experimental (5) 5
metabolites (5) 5
models, biological (5) 5
molecular sequence data (5) 5
organic anion transporters, sodium-independent - genetics (5) 5
p-glycoprotein (5) 5
physiological aspects (5) 5
polymorphism, genetic (5) 5
proteasome inhibitors - pharmacology (5) 5
protein binding (5) 5
research (5) 5
transporter (5) 5
amino acid sequence (4) 4
antineoplastic agents - administration & dosage (4) 4
antineoplastic agents - pharmacology (4) 4
beer (4) 4
bicarbonates - metabolism (4) 4
biotechnology (4) 4
blood (4) 4
bortezomib (4) 4
calcium - metabolism (4) 4
carrier proteins - metabolism (4) 4
cell membrane - metabolism (4) 4
cells, cultured (4) 4
chemistry, multidisciplinary (4) 4
colon (4) 4
compositions or test papers therefor (4) 4
condition-responsive control in microbiological orenzymological processes (4) 4
drug delivery systems (4) 4
drug design (4) 4
drug dosages (4) 4
drug interactions (4) 4
enzymology (4) 4
genetic polymorphisms (4) 4
genetic variation (4) 4
genotype (4) 4
hct116 cells (4) 4
immunohistochemistry (4) 4
in-vitro (4) 4
lung neoplasms - drug therapy (4) 4
mass spectrometry (4) 4
maximum tolerated dose (4) 4
measuring or testing processes involving enzymes, nucleicacids or microorganisms (4) 4
medicine & public health (4) 4
messenger-rna (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 03/2017, Volume 23, Issue 5, pp. 1299 - 1311
Purpose: Histone deacetylase inhibitors (HDI) are promising anticancer therapies; however, drug resistance limits their efficacy. Here, we investigated the... 
REAL-TIME PCR | LUNG-CANCER | CLINICAL-TRIAL | ONCOLOGY | SUBEROYLANILIDE HYDROXAMIC ACID | ANTITUMOR ACTION | TUMOR-SUPPRESSOR GENE | CTCF-BINDING | T-CELL LYMPHOMA | FACTOR RECEPTOR | CANCER-THERAPY | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Histone Deacetylases - genetics | Humans | CCCTC-Binding Factor - genetics | Lung Neoplasms - pathology | DNA Methylation - genetics | Hematologic Neoplasms - pathology | RNA, Long Noncoding - genetics | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | DNA (Cytosine-5-)-Methyltransferase 1 - genetics | Insulin-Like Growth Factor II - genetics | Lung Neoplasms - secondary | Hematologic Neoplasms - drug therapy | Hydroxamic Acids - administration & dosage | Hematologic Neoplasms - genetics | Mice | Gene Expression Regulation, Neoplastic - drug effects | Histone Deacetylase Inhibitors - adverse effects | STAT3 Transcription Factor - genetics | Histone deacetylase | Deregulation | Bisulfite | Lung cancer | Insulin-like growth factors | Drug resistance | Gene sequencing | Imprinting | Xenografts | Bioindicators | Insulin-like growth factor II | Deoxyribonucleic acid--DNA | DNMT1 protein | Stat3 protein | Insulin | Resistance factors | Molecular modelling | Inhibitors | Experimental design | Biomarkers | DNA methyltransferase | Methylation | Viability | Combinatorial analysis | Binding sites | Cancer | Tumors | DNA sequencing | Index Medicus | DNA methyltransferase 1 | insulin-like growth factor 2 | drug resistance | histone deacetylase inhibitor
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 02/2015, Volume 58, Issue 4, pp. 2036 - 2041
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2017, Volume 12, Issue 3, pp. e0173247 - e0173247
Journal Article
by Choo, SY and Yoon, SH and Lee, DJ and Lee, SH and Li, K and Koo, IH and Lee, W and Bae, SC and Lee, YM
INTERNATIONAL JOURNAL OF ONCOLOGY, ISSN 1019-6439, 04/2019, Volume 54, Issue 4, pp. 1327 - 1336
Endothelial progenitor cells (EPCs) are bone marrow (BM)-derived progenitor cells that can differentiate into mature endothelial cells, contributing to... 
vasculogenesis | METASTASIS | ANGIOGENESIS | CHEMOTAXIS | BONE-MARROW | endothelial progenitor cell | hypoxia-inducible factor | vascular endothelial growth factor receptor 2 signaling | HYPOXIA | ischemia | REPRESSION | ONCOLOGY | GROWTH-FACTOR | Runx3 | EXPRESSION | T-CELLS
Journal Article
SCIENTIFIC REPORTS, ISSN 2045-2322, 03/2019, Volume 9, Issue 1, pp. 4089 - 9
The second-in-class proteasome inhibitor (PI) carfilzomib (Kyprolis, Cfz) has contributed to a substantial advancement in multiple myeloma treatment by... 
OVEREXPRESSION | DEXAMETHASONE | SUBTYPES | MULTIDISCIPLINARY SCIENCES | LENALIDOMIDE | PHASE-2 | BORTEZOMIB | DIFFER | 20S PROTEASOMES | PROBES | Ubiquitin | Cell culture | Cell survival | γ-Interferon | Multiple myeloma | Proteasomes | siRNA | Patients | Proteasome inhibitors | Quality of life | Catalytic subunits
Journal Article
Drug Metabolism and Pharmacokinetics, ISSN 1347-4367, 01/2017, Volume 32, Issue 1, pp. S14 - S14
Journal Article
Journal Article
JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0022-2623, 05/2019, Volume 62, Issue 9, pp. 4444 - 4455
Over the past 15 years, proteasome inhibitors (PIs), namely bortezomib, carfilzomib (Cfz) and ixazomib, have significantly improved the overall survival and... 
OPROZOMIB | CELLS | APOPTOSIS | CHEMISTRY, MEDICINAL | REFRACTORY MULTIPLE-MYELOMA | EFFICACY | METABOLISM | IMMUNOPROTEASOME | MICROSOMAL EPOXIDE HYDROLASE | SMALL-MOLECULE INHIBITOR
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2013, Volume 8, Issue 9, pp. e73732 - e73732
The proteasome is a key regulator of cellular protein homeostasis and is a clinically validated anticancer target. The immunoproteasome, a subtype of... 
MHC CLASS-I | GENE | MULTIDISCIPLINARY SCIENCES | DISEASE | ANTIGEN-PROCESSING MACHINERY | LMP2 POLYMORPHISM | MAJOR HISTOCOMPATIBILITY COMPLEX | PROTEASOME INHIBITORS | ASSOCIATION | CELL CARCINOMA | AMERINDIANS | Immunohistochemistry | Colonic Neoplasms - genetics | Tissue Array Analysis | Humans | Gene Expression Regulation, Neoplastic | Fluorescent Dyes - metabolism | Immunoblotting | Cysteine Endopeptidases - metabolism | MCF-7 Cells | Neoplasms - genetics | Codon - genetics | Biocatalysis | HCT116 Cells | Pancreatic Neoplasms - pathology | Catalytic Domain - genetics | Pancreatic Neoplasms - enzymology | Neoplasms - enzymology | Genotype | Pancreatic Neoplasms - genetics | Polymorphism, Genetic | Gene Expression Regulation, Enzymologic | Hydrolysis | Colonic Neoplasms - pathology | Cysteine Endopeptidases - genetics | Cell Line, Tumor | Colonic Neoplasms - enzymology | Neoplasms - pathology | Amino Acid Substitution | Cellular proteins | Care and treatment | Colon cancer | Codon | Analysis | Pancreatic cancer | Genetic aspects | Genetic polymorphisms | Cancer | Antigen presentation | Biotechnology | Antigens | Immune response | Disease | Homeostasis | Catalytic activity | Tumor cell lines | Gene polymorphism | Substrates | Hemopoiesis | Immune systems | Genetic variance | Pharmacy | Cell lines | Catalysis | Colon | Autoimmune diseases | Pharmaceutical sciences | Apoptosis | Polymorphism | Index Medicus
Journal Article
Biopharmaceutics & Drug Disposition, ISSN 0142-2782, 09/2015, Volume 36, Issue 6, pp. 410 - 415
The pharmacokinetics of lobeglitazone (LB) was studied after intravenous administration at a dose of 1 mg/kg and oral administration at doses of 0.1, 1 and 10... 
pharmacokinetics | gender difference | rats | lobeglitazone | hepatic elimination | CYTOCHROME-P450 | ACTIVATED RECEPTOR-GAMMA | DRUG DISCOVERY | PIOGLITAZONE | METABOLISM | CKD-501 | PHARMACOLOGY & PHARMACY | ROSIGLITAZONE
Journal Article